Takeda CEO prescribes R&D cuts after Shire deal (Reuters)
Novasecta’s Managing Partner, John Rountree, was asked by Reuters to reflect on Christophe Weber’s, CEO of Takeda, comments on the cuts to R&D after their deal with Shire: “They are cutting quite deep in R&D and it is not clear if the amount of money they are saving is going to be beneficial or harmful. […]
Takeda’s takeover of Shire (CNBC)
Novasecta’s Managing Partner, John Rountree, was asked by CNBC to comment on Takeda’s takeover of Shire, in which he reflects on “M&A becoming very expensive in pharma” and how the “innovation problem drives M&A in the sector”, both issues Novasecta has previously highlighted. To read our insight into the cost of pharma M&A click here or for […]